(ELVN) Enliven Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29337E1029
ELVN: Cancer, Leukemia, Solid, Tumors, Inhibitors
Enliven Therapeutics Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company dedicated to advancing innovative cancer treatments through the development of small molecule inhibitors. These inhibitors are designed to target specific pathways critical for cancer cell growth and survival, offering a promising approach to precision oncology. The company’s lead candidate, ELVN-001, is currently in a Phase 1 clinical trial for adults with chronic myeloid leukemia (CML), a type of blood cancer characterized by the uncontrolled growth of myeloid cells. CML often develops resistance to existing therapies, making ELVN-001 a potential game-changer for patients in need of new treatment options.
Enliven is also investigating ELVN-002 in a Phase 1 clinical trial for adults with solid tumors harboring HER2 alterations. HER2 is a well-known target in oncology, particularly in breast cancer, but its role in other solid tumors presents an opportunity for expansion. By focusing on HER2-altered tumors, Enliven is addressing a subset of cancers that may not respond adequately to current therapies. This targeted approach aligns with the broader trend in oncology toward precision medicine, where treatments are tailored to the molecular characteristics of a patient’s disease.
Headquartered in Boulder, Colorado, Enliven operates in a vibrant biotech ecosystem that fosters innovation and collaboration. The company’s focus on small molecule inhibitors is strategic, as these compounds can often be administered orally and have the potential for broader therapeutic applications. Investors and fund managers should note that Enliven is still in the early stages of clinical development, which carries inherent risks but also significant upside potential if its candidates prove successful in later-stage trials.
From a financial perspective, Enliven Therapeutics has a market capitalization of approximately $1.059 billion, reflecting investor confidence in its pipeline and strategy. The company’s price-to-book (P/B) ratio of 3.67 suggests that investors are valuing its assets and intellectual property at a premium. However, with a P/E ratio of 0, the company is not yet profitable, which is typical for a clinical-stage biotech firm. As with any biopharmaceutical investment, the key risks revolve around clinical trial outcomes, regulatory approvals, and the competitive landscape in oncology.
Additional Sources for ELVN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ELVN Stock Overview
Market Cap in USD | 991m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2020-03-12 |
ELVN Stock Ratings
Growth 5y | -43.7% |
Fundamental | -42.9% |
Dividend | 0.0% |
Rel. Strength Industry | 78.2 |
Analysts | 4.88/5 |
Fair Price Momentum | 17.45 USD |
Fair Price DCF | - |
ELVN Dividends
No Dividends PaidELVN Growth Ratios
Growth Correlation 3m | -82.3% |
Growth Correlation 12m | 24.5% |
Growth Correlation 5y | -35.8% |
CAGR 5y | -19.64% |
CAGR/Max DD 5y | -0.20 |
Sharpe Ratio 12m | -0.21 |
Alpha | 61.99 |
Beta | 2.08 |
Volatility | 65.00% |
Current Volume | 205.4k |
Average Volume 20d | 177.6k |
As of March 15, 2025, the stock is trading at USD 20.74 with a total of 205,365 shares traded.
Over the past week, the price has changed by -1.24%, over one month by -4.34%, over three months by -12.01% and over the past year by +79.72%.
Probably not. Based on ValueRay Fundamental Analyses, Enliven Therapeutics (NASDAQ:ELVN) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -42.89 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ELVN as of March 2025 is 17.45. This means that ELVN is currently overvalued and has a potential downside of -15.86%.
Enliven Therapeutics has received a consensus analysts rating of 4.88. Therefor, it is recommend to buy ELVN.
- Strong Buy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ELVN Enliven Therapeutics will be worth about 20.2 in March 2026. The stock is currently trading at 20.74. This means that the stock has a potential downside of -2.41%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 37.9 | 82.5% |
Analysts Target Price | 37.9 | 82.5% |
ValueRay Target Price | 20.2 | -2.4% |